The DOI matches its Crossref record; 21 of the 21 references it cites were found in a registry or an index.
The Efficacy and Safety of Tigecycline in the Treatment of Skin and Skin‐Structure Infections: Results of 2 Double‐Blind Phase 3 Comparison Studies with Vancomycin‐Aztreonam
Abstract
Two phase 3, double-blind studies in hospitalized adults with complicated skin and skin-structure infections (cSSSI) determined the safety and efficacy of tigecycline versus that of vancomycin-aztreonam. Patients received tigecycline (100 mg, followed by 50 mg intravenously twice daily) or vancomycin (1 g intravenously twice daily) plus aztreonam (2 g intravenously twice daily) for up to 14 days. Populations were as follows: 1116 patients (566 treated with tigecycline, and 550 treated with vancomycin-aztreonam) constituted the modified intent-to-treat (mITT) population, 1057 patients (538 treated with tigecycline, and 519 treated with vancomycin-aztreonam) constituted the clinical mITT (c-mITT) population, and 833 patients (422 treated with tigecycline, and 411 treated with vancomycin-aztreonam) constituted the clinically evaluable population. Clinical responses to tigecycline and vancomycin-aztreonam at test-of-cure were similar: c-mITT, 79.7% (95% confidence interval [CI], 76.1%-83.1%) versus 81.9% (95% CI, 78.3%-85.1%) (P = .4183); and clinically evaluable, 86.5% (95% CI, 82.9%-89.6%) versus 88.6% (95% CI, 85.1%-91.5%) (P = .4233). Adverse events were similar, with increased nausea and vomiting in the tigecycline group and increased rash and elevated hepatic aminotransferase levels in the vancomycin-aztreonam group. Tigecycline monotherapy is as safe and efficacious as the vancomycin-aztreonam combination in treating patients with cSSSI.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
THE USE OF CONFIDENCE OR FIDUCIAL LIMITS ILLUSTRATED IN THE CASE OF THE BINOMIAL
CLOPPER, C. J., & PEARSON, E. S. (1934) · Biometrika · doi:10.1093/biomet/26.4.404 · Cited by 5,003
Probable Inference, the Law of Succession, and Statistical Inference
Wilson, E. B. (1927) · Journal of the American Statistical Association · doi:10.1080/01621459.1927.10502953 · Cited by 4,476
Arky, R. A. (1994) · Cited by 2,632
Naimi, T. S. (2003) · JAMA · doi:10.1001/jama.290.22.2976 · Cited by 1,688
An overview of nosocomial infections, including the role of the microbiology laboratory
Emori, T. G., & Gaynes, R. P. (1993) · Clinical Microbiology Reviews · doi:10.1128/cmr.6.4.428 · Cited by 1,286
Performance Standards for Antimicrobial Disk Susceptibility Tests; Approved Standard
Wikler, M. A., & Clinical (2012) · Medical Entomology and Zoology · Cited by 895
Pfaller, M. A., Jones, R. N., Doern, G. V., Kugler, K., & Group, T. S. P. (1998) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.42.7.1762 · Cited by 539
Petersen, P. J., Jacobus, N. V., Weiss, W. J., Sum, P. E., & Testa, R. T. (1999) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.43.4.738 · Cited by 415
Increasing Resistance to Vancomycin and Other Glycopeptides in Staphylococcus aureus
Tenover, F. C., Biddle, J. W., & Lancaster, M. V. (2001) · Emerging Infectious Diseases · doi:10.3201/eid0702.010237 · Cited by 391
The Glycylcyclines: A Comparative Review with the Tetracyclines
Zhanel, G. G., Homenuik, K., Nichol, K., Noreddin, A., Vercaigne, L., Embil, J., Gin, A., Karlowsky, J. A., & Hoban, D. J. (2004) · Drugs · doi:10.2165/00003495-200464010-00005 · Cited by 306
Vancomycin-resistant Staphylococcus aureus--New York, 2004.
(2004) · PubMed · Cited by 252
Boyce, J. M. (1992) · Infection Control & Hospital Epidemiology · doi:10.1086/648346 · Cited by 197
Gales, A. C., & Jones, R. N. (2000) · Diagnostic Microbiology and Infectious Disease · doi:10.1016/s0732-8893(99)00092-9 · Cited by 189
Summanen, P. H., Talan, D. A., Strong, C., McTeague, M., Bennion, R., Thompson, J. E., Väisänen, M.-L., Moran, G., Winer, M., & Finegold, S. M. (1995) · Clinical Infectious Diseases · doi:10.1093/clinids/20.supplement_2.s279 · Cited by 177
Sum, P.-E., & Petersen, P. (1999) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/s0960-894x(99)00216-4 · Cited by 173
Doern, G. V., Jones, R. N., Pfaller, M. A., Kugler, K. C., & Beach, M. L. (1999) · Diagnostic Microbiology and Infectious Disease · doi:10.1016/s0732-8893(98)00162-x · Cited by 140
Clinical Presentations of Soft‐Tissue Infections and Surgical Site Infections
Nichols, R. L., & Florman, S. S. (2001) · Clinical Infectious Diseases · doi:10.1086/321862 · Cited by 125
Glycylcyclines: third-generation tetracycline antibiotics
Chopra, I. (2001) · Current Opinion in Pharmacology · doi:10.1016/s1471-4892(01)00081-9 · Cited by 122
Biedenbach, D. J., Beach, M. L., & Jones, R. N. (2001) · Diagnostic Microbiology and Infectious Disease · doi:10.1016/s0732-8893(01)00269-3 · Cited by 102
Falagas, M. E., Barefoot, L., Griffith, J., Ruthazar, R., & Snydman, D. R. (1996) · European Journal of Clinical Microbiology & Infectious Diseases · doi:10.1007/bf01690508 · Cited by 92
Hoellman, D. B., Pankuch, G. A., Jacobs, M. R., & Appelbaum, P. C. (2000) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.44.4.1085-1088.2000 · Cited by 65
Cited by
Tong, S. Y. C., Davis, J. S., Eichenberger, E., Holland, T. L., & Fowler, V. G. (2015) · Clinical Microbiology Reviews · doi:10.1128/cmr.00134-14 · Cited by 5,192
Liu, C., Bayer, A., Cosgrove, S. E., Daum, R. S., Fridkin, S. K., Gorwitz, R. J., Kaplan, S. L., Karchmer, A. W., Levine, D. P., Murray, B. E., et al. (2011) · Clinical Infectious Diseases · doi:10.1093/cid/ciq146 · Cited by 4,191
Acinetobacter baumannii : Emergence of a Successful Pathogen
Peleg, A. Y., Seifert, H., & Paterson, D. L. (2008) · Clinical Microbiology Reviews · doi:10.1128/cmr.00058-07 · Cited by 3,316
Methicillin-resistant Staphylococcus aureus: an overview of basic and clinical research
Turner, N. A., Sharma-Kuinkel, B. K., Maskarinec, S. A., Eichenberger, E. M., Shah, P. P., Carugati, M., Holland, T. L., & Fowler, V. G. (2019) · Nature Reviews Microbiology · doi:10.1038/s41579-018-0147-4 · Cited by 2,051
Practice Guidelines for the Diagnosis and Management of Skin and Soft-Tissue Infections
Stevens, D. L., Bisno, A. L., Chambers, H. F., Everett, E. D., Dellinger, P., Goldstein, E. J. C., Gorbach, S. L., Hirschmann, J. V., Kaplan, E. L., Montoya, J. G., et al. (2005) · Clinical Infectious Diseases · doi:10.1086/497143 · Cited by 1,602
Metadata
- Authors
- Ellis‐Grosse, E. J., Babinchak, T., Dartois, N., Rose, G., Loh, E., & Groups, T. 3. A. 3. C. S.
- Venue
- Clinical Infectious Diseases
- Publisher
- Oxford University Press (OUP)
- Published
- 2005-09
- Volume
- 41
- Issue
- s5
- Pages
- S341-S353
- ISSN
- 1058-4838 (ISSN-L)
- 1537-6591
- OpenAlex
- W2040587302
- Cited by
- 414
- References
- 21
- FWCI
- 26.81
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.